Enkephalins Drive Feeding Motivation and Weight Gain While β-Endorphin Controls Taste Pleasure

Knockout mice studies reveal that enkephalins primarily regulate feeding motivation and diet-induced weight gain, while β-endorphin modulates how rewarding food tastes — explaining why broad opioid-blocking drugs fail for obesity.

RPEP-027402015RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Proenkephalin knockout (PENK KO) mice showed reduced feeding motivation — fewer licking bouts for sucrose but normal bout lengths — and had lower baseline body weight on regular chow and attenuated weight gain on an energy-dense cafeteria diet.

β-endorphin-deficient (BEND KO) mice showed altered taste reward — shorter licking bouts (suggesting reduced palatability) but normal bout frequency. Critically, BEND KO mice were insensitive to shifts in sucrose concentration and hunger state, indicating β-endorphin specifically mediates orosensory reward responses under conditions of high need or high stimulus value.

PENK KO but not BEND KO mice showed resistance to diet-induced obesity, demonstrating that enkephalins — not β-endorphin — are the primary opioid peptides regulating body weight through motivational tone.

Key Numbers

How They Did This

The study used proenkephalin knockout (PENK KO) and β-endorphin-deficient (BEND KO) mice compared to wild-type controls. Palatable liquid consumption was measured using detailed lickometer analysis (bout frequency and bout length) with sucrose solutions at varying concentrations. Body weight was tracked during consumption of standard chow and an energy-dense 'cafeteria diet.' Sensitivity to sucrose concentration shifts and hunger states was assessed to distinguish motivational from hedonic components of feeding.

Why This Research Matters

Obesity is a global epidemic, and the opioid system in the brain has long been a target for appetite-suppressing drugs. But drugs that broadly block mu-opioid receptors (like naltrexone) have shown limited long-term efficacy for weight control. This study explains why: enkephalins and β-endorphin have fundamentally different roles in eating behavior, and blocking both simultaneously may counterproductively disrupt the system. More targeted approaches — specifically addressing enkephalin-mediated motivation — might be more effective for obesity treatment.

The Bigger Picture

This study elegantly dissects the 'wanting' (motivation, enkephalin-mediated) versus 'liking' (hedonic reward, β-endorphin-mediated) distinction in feeding behavior — a framework influential in addiction and obesity research. By showing that these two opioid peptide systems independently control different aspects of eating, it provides a neurochemical basis for more precise pharmacological interventions. The finding also connects to the broader understanding that the opioid system modulates reward processing across many domains, not just pain.

What This Study Doesn't Tell Us

The study was conducted in genetically modified mice, and compensatory developmental changes in knockout animals may confuse interpretation. Human opioid system regulation of feeding may differ. The cafeteria diet model, while useful, doesn't fully replicate human eating patterns. The study focused on sucrose consumption as a measure of palatability, which may not generalize to all food types. Specific neural circuits mediating these peptide effects were not identified.

Questions This Raises

  • ?Could drugs that selectively block enkephalin signaling (without affecting β-endorphin) be more effective for obesity than current broad opioid antagonists?
  • ?Do humans with naturally lower enkephalin levels show less diet-induced weight gain, similar to the PENK KO mice?
  • ?How do enkephalin and β-endorphin interact with other appetite-regulating systems like GLP-1 and ghrelin?

Trust & Context

Key Stat:
Enkephalins = motivation, β-endorphin = reward Mice lacking enkephalins ate less and resisted diet-induced obesity, while mice lacking β-endorphin showed altered taste pleasure but normal weight — revealing distinct peptide roles in feeding
Evidence Grade:
This is a well-designed preclinical study published in Neuropsychopharmacology using genetic knockout models with detailed behavioral analysis. The double-dissociation between PENK and BEND knockouts provides compelling mechanistic evidence, though translation to human obesity treatment requires further work.
Study Age:
Published in 2015, this study contributed important mechanistic insights to the 'wanting vs liking' framework in feeding behavior and remains relevant to ongoing opioid-system-based obesity drug development efforts.
Original Title:
Involvement of Endogenous Enkephalins and β-Endorphin in Feeding and Diet-Induced Obesity.
Published In:
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(9), 2103-12 (2015)
Database ID:
RPEP-02740

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What's the difference between 'wanting' and 'liking' food?

In neuroscience, 'wanting' (motivation) is the drive to seek out and eat food, while 'liking' (hedonic reward) is how pleasurable food tastes. This study found that enkephalins control the 'wanting' aspect — how motivated you are to eat — while β-endorphin controls 'liking' — how good the food tastes, especially when you're hungry or the food is particularly appealing.

Why haven't opioid-blocking drugs worked well for weight loss?

Drugs like naltrexone block all opioid receptors indiscriminately, disrupting both the motivation to eat (enkephalin-mediated) and the pleasure of eating (β-endorphin-mediated). This study suggests that specifically targeting the enkephalin motivation system — while leaving taste reward intact — might be a more effective and tolerable approach to treating obesity.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-02740·https://rethinkpeptides.com/research/RPEP-02740

APA

Mendez, Ian A; Ostlund, Sean B; Maidment, Nigel T; Murphy, Niall P. (2015). Involvement of Endogenous Enkephalins and β-Endorphin in Feeding and Diet-Induced Obesity.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(9), 2103-12. https://doi.org/10.1038/npp.2015.67

MLA

Mendez, Ian A, et al. "Involvement of Endogenous Enkephalins and β-Endorphin in Feeding and Diet-Induced Obesity.." Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. https://doi.org/10.1038/npp.2015.67

RethinkPeptides

RethinkPeptides Research Database. "Involvement of Endogenous Enkephalins and β-Endorphin in Fee..." RPEP-02740. Retrieved from https://rethinkpeptides.com/research/mendez-2015-involvement-of-endogenous-enkephalins

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.